HOLON, Israel, January 2, 2018 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery
and development of first-in-class therapeutics for cancer
immunotherapy, today announced upcoming poster and oral
presentations on COM701, a first-in-class therapeutic antibody
candidate targeting PVRIG, and COM902, a therapeutic antibody
targeting TIGIT, at the following immunotherapy conferences:
The poster titled "PVRIG Expression is Associated with T Cell
Exhaustion and Synergizes with TIGIT to Inhibit Anti-Tumor
Responses" (Poster no. 2028) will be presented on Thursday,
January 18, 2018 at the Keystone Symposia Conference, A3: T
Cell Dysfunction, Cancer and Infection, being held January 16-20, 2018 at the Beaver Run Resort,
Breckenridge, CO. The poster will
include new preclinical data further supporting COM701's potential
efficacy as monotherapy and in combination with other checkpoint
inhibitors, as well as the importance of targeting PVRIG in
treating certain cancers.
The presentation titled "Targeting PVRIG and TIGIT for Cancer
Immunotherapy" will be given on Tuesday,
January 23, 2018 at the Precision Medicine World Conference
being held January 22-24, 2018 at the
Computer History Museum, Mountain View,
CA.
The presentation titled "Antagonism of PVRIG, a Novel Checkpoint
Receptor, Potentiates Anti-Tumor Responses" will be given on
Wednesday, February 14, 2018 at the
Molecular Medicine Tri-Conference being held February 11-16, 2018 at the Moscone South
Convention Center, San Francisco,
CA.
Following these presentations, the poster and presentation
slides will be available on Compugen's website at
http://www.cgen.com.
About COM701 and COM902
COM701 is a humanized hybridoma antibody that binds with high
affinity to PVRIG, a novel B7/CD28-like immune checkpoint target
candidate discovered by Compugen, indicating blockage of this
target's interaction with PVRL2. Blockade of PVRIG by COM701 has
demonstrated potent, reproducible enhancement of T cell activation,
consistent with the desired mechanism of action of activating T
cells in the tumor microenvironment to generate anti-tumor immune
responses. In addition, COM701 combined with antagonist anti-PD1
antibodies has demonstrated synergistic effect on human T cell
stimulation, indicating the potential of these combinations to
further enhance immune response against tumors.
COM902, Compugen's antibody targeting TIGIT, was developed for
combination use with COM701. Preclinical data strongly support the
dual blockade of the two negative costimulatory arms of the axis -
TIGIT and PVRIG - that results in a more robust T cell response to
antigen stimulation, and therefore may result in an enhanced
anti-tumor immune response.
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," "confident," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties,
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors, including the
ability to finance the Company, are more fully discussed in the
"Risk Factors" section of Compugen's most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
SOURCE Compugen Ltd.